Jennifer J. Davagian

Founder/Chief Executive Officer

Jennifer J. Davagian founded Cristcot in 2008 and is named inventor of all the company’s patented technologies, including but not limited to, medical devices, manufacturing processes, drug assay testing methods, and the drug formulations. Drawing on prior business leadership and technical innovation experience, she established Cristcot as a global development and research company with capabilities spanning drug formulation, device engineering, and clinical development. Jennifer directs all of the Company’s operations from finance and administration to manufacturing, non-clinical and clinical research, regulatory strategy and FDA interactions. She earned her B.A. from Furman University.

Mark C. Ensign

Founder/Chief Operating Officer/Chief Scientific Officer

Mark C. Ensign joined Cristcot in 2014 and serves as both Chief Operating Officer and Chief Scientific Officer, guiding the Company’s scientific strategy, product development, and operational and manufacturing execution. His expertise spans medical device engineering, suppository formulation and development, and the testing, validation, and scale-up of drug–device combination products. Mark’s prior experience as a senior scientist and project lead informs his oversight of Cristcot’s research programs, technology development, and commercial readiness. He holds dual B.A. and B.S. degrees from Furman University and an M.S. from Wright State University.

Mark A. Parent

Chief Financial Officer

Mark A. Parent joined Cristcot in 2015 and serves as Chief Financial Officer, bringing more than 25 years of experience in financial operations, strategic planning, and capital management. He has supported companies from early-stage formation through pre-IPO and transactional readiness and has deep expertise in forecasting, cash flow modeling, and financial controls. Mark oversees Cristcot’s finance operations and leads the development of audit, cash flow, budget, and long-term financial projections. He previously served as President of MAP Advisors and holds a B.S. from Northeastern University.

Jenny Gizzi

Chief Administration Officer

Jenny Gizzi serves as Chief Administration Officer and brings more than 20 years of leadership experience across major pharmaceutical and biotechnology organizations. She has a strong track record in business growth, operational transformation, and the implementation of enterprise systems that support scalability and compliance. Jenny leads Cristcot’s administrative, IT, and operational infrastructure, ensuring that technology, process, and organizational systems are aligned with the Company’s operational, financial, scientific, and commercial objectives. She holds a B.A. from Fairleigh Dickinson University.

Board Members

• Ernest Pomerantz - Private Investor, formerly of Warburg Pincus

• Marc Keller - Private Investor, Senior Executive at CIBC Private Wealth

• Henry Kay - Private Investor, formerly of Allergan and Boston Scientific

• John S. Davagian II - Private Investor, Attorney

• Richard Warburg - Patent Attorney, experienced executive in FDA approvals for pharmaceuticals and devices

• David Shepard - Private Investor, Principal at Shepherd Kaplan Krochuk,  LLC

• Rory Riggs (Observer) - Co-founder of Royalty Pharma, Founder and CEO of Cibus, Syntax & Locus Analytics

• Erik Oros (observer) - Chief Investment Officer, Gideon Strategic Partners.